2026
A+ VERIFIED
Abfm Ksa Diabetes Certification Exam Actual 2026 2027 Practice
Questions And Study Guide Complete Accurate Exam Approved
Questions With Well Elaborated Answers And Detailed Rationales
Instant Download 98 Questions
Clinical | Rationale-Driven - Pass Guaranteed - A+ Graded
98 1 98
QUESTIONS SECTIONS RATIONALES
WHAT THIS COVERS
01 Diabetes Mellitus Management (Family Medicine)
02 Aligned with the ABFM Knowledge Self-Assessment (KSA) module. It covers diagnosis
03 Pharmacotherapy
04 Complications
05 Special populations
06 Current standards of care
ABOUT THIS ASSESSMENT
This exam assesses the knowledge and clinical reasoning required of board-certified family physicians in the management of
diabetes mellitus, aligned with the ABFM Knowledge Self-Assessment (KSA) module. It covers diagnosis, pharmacotherapy,
complications, special populations, and current standards of care.
,EXAMINATION QUESTIONS
SECTION 1 - Diabetes Mellitus Management (Family Medicine) (Questions 1 to 98)
1. Which of the following is the most appropriate initial insulin regimen for a patient with type 2 diabetes and an A1c of
9.5% who is symptomatic?
A. Basal insulin alone
B. Premixed insulin twice daily
C. Basal-bolus regimen
D. Sliding-scale insulin only
Answer: C [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: For markedly symptomatic patients with A1c >9.5%, ADA recommends considering basal-bolus insulin to address both
fasting and postprandial hyperglycemia. Basal insulin alone may not adequately control symptoms; premixed and sliding-scale are less
physiologic and not preferred.
2. A patient on empagliflozin develops euglycemic DKA. Which mechanism best explains the absence of marked
hyperglycemia?
A. Increased renal glucose clearance
B. Enhanced peripheral insulin sensitivity
C. Reduced hepatic gluconeogenesis
D. Suppressed ketone utilization
Answer: A [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: SGLT2 inhibitors promote glycosuria, lowering plasma glucose even as ketogenesis increases, so DKA can occur without
severe hyperglycemia. The other options do not account for the euglycemic presentation.
3. A patient with type 2 diabetes on insulin develops hypoglycemia unawareness. Which strategy is most appropriate?
A. Increase basal insulin to stabilize glucose
B. Relax glycemic targets and avoid hypoglycemia for several weeks
C. Add a sulfonylurea to smooth glucose fluctuations
D. Switch to a fixed-dose premixed insulin regimen
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: Hypoglycemia unawareness is reversed by scrupulous avoidance of hypoglycemia for 2-4 weeks, which restores
counterregulatory and symptomatic responses. This requires relaxing targets and adjusting insulin. Increasing basal insulin, adding a
sulfonylurea, or using fixed-dose premixed insulin all increase hypoglycemia risk and worsen unawareness.
4. Which is the preferred treatment for hypoglycemia in a conscious patient with diabetes?
A. 15-20 g fast-acting oral carbohydrate
B. Subcutaneous glucagon
C. Intravenous dextrose
D. Oral acarbose
Answer: A [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: For conscious hypoglycemia, 15-20 g fast-acting oral carbohydrate is first-line. IV dextrose or glucagon is for
severe/unconscious cases; acarbose is not appropriate. Thus A is correct.
Page 2 | Abfm Ksa Diabetes Certification Exam Actual 2026 2027 Practice Questions And Study Guide Complete Accurate Exam Approved
, 5. Which medication class should be avoided in a patient with type 2 diabetes and a history of medullary thyroid
carcinoma?
A. SGLT2 inhibitors
B. GLP-1 receptor agonists
C. DPP-4 inhibitors
D. Sulfonylureas
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: GLP-1 receptor agonists carry a boxed warning for medullary thyroid carcinoma and should not be used in patients with a
personal or family history of MTC or MEN2. SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas do not have this contraindication.
6. Which most accurately describes the recommended management of diabetic retinopathy in a patient with type 2
diabetes and HbA1c 9.5%?
A. Immediate panretinal photocoagulation for all retinopathy
B. Optimize glycemic control and refer for dilated eye exam; treat vision-threatening retinopathy with anti-VEGF
or laser
C. Start aspirin to prevent progression
D. Restrict physical activity to avoid retinal detachment
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: Optimal glycemic control and regular dilated eye exams are foundational; vision-threatening retinopathy (e.g., proliferative
or macular edema) warrants anti-VEGF or laser therapy. Panretinal photocoagulation is not for all retinopathy. Aspirin does not
prevent retinopathy progression, and activity restriction is unnecessary.
7. Which intervention most effectively reduces progression of diabetic retinopathy in a patient with type 2 diabetes and
hypertension?
A. Intensive glycemic control alone
B. Blood pressure control to below 130/80 mmHg
C. Annual intravitreal anti-VEGF injections
D. Aspirin 325 mg daily
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: Blood pressure control (<130/80 mmHg) is a major modifiable risk factor for retinopathy progression, and tight BP control
reduces both microvascular and macrovascular events. Intensive glycemic control helps but is not the sole intervention; anti-VEGF is
reserved for macular edema or proliferative disease, and aspirin is not indicated for retinopathy prevention.
8. Which best explains why SGLT2 inhibitors reduce heart failure hospitalization in type 2 diabetes?
A. Increased natriuresis and reduced cardiac preload
B. Direct beta-adrenergic receptor blockade
C. Increased hepatic gluconeogenesis
D. Stimulation of insulin secretion from beta cells
Answer: A [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: SGLT2 inhibitors promote glycosuria and natriuresis, reducing plasma volume and cardiac preload, with additional effects
on myocardial energetics and inflammation; these mechanisms underlie reduced HF hospitalization independent of glycemic control.
They do not block beta receptors, increase gluconeogenesis, or stimulate insulin secretion (those describe beta-blockers,
metformin/glucagon, and sulfonylureas/GLP-1 RAs, respectively).
9. Which parameter is the strongest predictor of CGM-measured glycemic variability?
A. Mean sensor glucose
B. Coefficient of variation
C. Time in range
D. Fasting glucose
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: The coefficient of variation (CV) directly quantifies dispersion of sensor glucose values and is the standard metric for
glycemic variability; CV 36% indicates unstable glycemia. Mean glucose, TIR, and fasting glucose reflect central tendency or target
attainment, not variability per se.
Page 3 | Abfm Ksa Diabetes Certification Exam Actual 2026 2027 Practice Questions And Study Guide Complete Accurate Exam Approved
A+ VERIFIED
Abfm Ksa Diabetes Certification Exam Actual 2026 2027 Practice
Questions And Study Guide Complete Accurate Exam Approved
Questions With Well Elaborated Answers And Detailed Rationales
Instant Download 98 Questions
Clinical | Rationale-Driven - Pass Guaranteed - A+ Graded
98 1 98
QUESTIONS SECTIONS RATIONALES
WHAT THIS COVERS
01 Diabetes Mellitus Management (Family Medicine)
02 Aligned with the ABFM Knowledge Self-Assessment (KSA) module. It covers diagnosis
03 Pharmacotherapy
04 Complications
05 Special populations
06 Current standards of care
ABOUT THIS ASSESSMENT
This exam assesses the knowledge and clinical reasoning required of board-certified family physicians in the management of
diabetes mellitus, aligned with the ABFM Knowledge Self-Assessment (KSA) module. It covers diagnosis, pharmacotherapy,
complications, special populations, and current standards of care.
,EXAMINATION QUESTIONS
SECTION 1 - Diabetes Mellitus Management (Family Medicine) (Questions 1 to 98)
1. Which of the following is the most appropriate initial insulin regimen for a patient with type 2 diabetes and an A1c of
9.5% who is symptomatic?
A. Basal insulin alone
B. Premixed insulin twice daily
C. Basal-bolus regimen
D. Sliding-scale insulin only
Answer: C [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: For markedly symptomatic patients with A1c >9.5%, ADA recommends considering basal-bolus insulin to address both
fasting and postprandial hyperglycemia. Basal insulin alone may not adequately control symptoms; premixed and sliding-scale are less
physiologic and not preferred.
2. A patient on empagliflozin develops euglycemic DKA. Which mechanism best explains the absence of marked
hyperglycemia?
A. Increased renal glucose clearance
B. Enhanced peripheral insulin sensitivity
C. Reduced hepatic gluconeogenesis
D. Suppressed ketone utilization
Answer: A [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: SGLT2 inhibitors promote glycosuria, lowering plasma glucose even as ketogenesis increases, so DKA can occur without
severe hyperglycemia. The other options do not account for the euglycemic presentation.
3. A patient with type 2 diabetes on insulin develops hypoglycemia unawareness. Which strategy is most appropriate?
A. Increase basal insulin to stabilize glucose
B. Relax glycemic targets and avoid hypoglycemia for several weeks
C. Add a sulfonylurea to smooth glucose fluctuations
D. Switch to a fixed-dose premixed insulin regimen
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: Hypoglycemia unawareness is reversed by scrupulous avoidance of hypoglycemia for 2-4 weeks, which restores
counterregulatory and symptomatic responses. This requires relaxing targets and adjusting insulin. Increasing basal insulin, adding a
sulfonylurea, or using fixed-dose premixed insulin all increase hypoglycemia risk and worsen unawareness.
4. Which is the preferred treatment for hypoglycemia in a conscious patient with diabetes?
A. 15-20 g fast-acting oral carbohydrate
B. Subcutaneous glucagon
C. Intravenous dextrose
D. Oral acarbose
Answer: A [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: For conscious hypoglycemia, 15-20 g fast-acting oral carbohydrate is first-line. IV dextrose or glucagon is for
severe/unconscious cases; acarbose is not appropriate. Thus A is correct.
Page 2 | Abfm Ksa Diabetes Certification Exam Actual 2026 2027 Practice Questions And Study Guide Complete Accurate Exam Approved
, 5. Which medication class should be avoided in a patient with type 2 diabetes and a history of medullary thyroid
carcinoma?
A. SGLT2 inhibitors
B. GLP-1 receptor agonists
C. DPP-4 inhibitors
D. Sulfonylureas
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: GLP-1 receptor agonists carry a boxed warning for medullary thyroid carcinoma and should not be used in patients with a
personal or family history of MTC or MEN2. SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas do not have this contraindication.
6. Which most accurately describes the recommended management of diabetic retinopathy in a patient with type 2
diabetes and HbA1c 9.5%?
A. Immediate panretinal photocoagulation for all retinopathy
B. Optimize glycemic control and refer for dilated eye exam; treat vision-threatening retinopathy with anti-VEGF
or laser
C. Start aspirin to prevent progression
D. Restrict physical activity to avoid retinal detachment
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: Optimal glycemic control and regular dilated eye exams are foundational; vision-threatening retinopathy (e.g., proliferative
or macular edema) warrants anti-VEGF or laser therapy. Panretinal photocoagulation is not for all retinopathy. Aspirin does not
prevent retinopathy progression, and activity restriction is unnecessary.
7. Which intervention most effectively reduces progression of diabetic retinopathy in a patient with type 2 diabetes and
hypertension?
A. Intensive glycemic control alone
B. Blood pressure control to below 130/80 mmHg
C. Annual intravitreal anti-VEGF injections
D. Aspirin 325 mg daily
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: Blood pressure control (<130/80 mmHg) is a major modifiable risk factor for retinopathy progression, and tight BP control
reduces both microvascular and macrovascular events. Intensive glycemic control helps but is not the sole intervention; anti-VEGF is
reserved for macular edema or proliferative disease, and aspirin is not indicated for retinopathy prevention.
8. Which best explains why SGLT2 inhibitors reduce heart failure hospitalization in type 2 diabetes?
A. Increased natriuresis and reduced cardiac preload
B. Direct beta-adrenergic receptor blockade
C. Increased hepatic gluconeogenesis
D. Stimulation of insulin secretion from beta cells
Answer: A [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: SGLT2 inhibitors promote glycosuria and natriuresis, reducing plasma volume and cardiac preload, with additional effects
on myocardial energetics and inflammation; these mechanisms underlie reduced HF hospitalization independent of glycemic control.
They do not block beta receptors, increase gluconeogenesis, or stimulate insulin secretion (those describe beta-blockers,
metformin/glucagon, and sulfonylureas/GLP-1 RAs, respectively).
9. Which parameter is the strongest predictor of CGM-measured glycemic variability?
A. Mean sensor glucose
B. Coefficient of variation
C. Time in range
D. Fasting glucose
Answer: B [Concept: Diabetes Mellitus Management (Family Medicine)]
Rationale: The coefficient of variation (CV) directly quantifies dispersion of sensor glucose values and is the standard metric for
glycemic variability; CV 36% indicates unstable glycemia. Mean glucose, TIR, and fasting glucose reflect central tendency or target
attainment, not variability per se.
Page 3 | Abfm Ksa Diabetes Certification Exam Actual 2026 2027 Practice Questions And Study Guide Complete Accurate Exam Approved
